Navigation Links
First of many Neuro-Biotech's licensed products, "SymPath(R) blood test"
Date:10/4/2010

uessing, medical practitioners will now be able to not only obtain accurate results, moreover, they will be able to properly diagnose their patients and prescribe the appropriate therapeutic approach and continued follow up with the patients.

SymPath(R) testing and its look into the intricate workings of the diverse mechanisms of the brain shall considerably reduce a patient's burden during these already difficult times, furnishing physicians with a medically proven test, allowing for precise, effective and speedy diagnosis.

Equally, the SymPath(R) test will also allow major employers and a multitude of organizations within the health industry such as insurance companies, health providers, health establishments and governments in their efforts in reducing inefficiencies and most importantly cost.

To obtain the background scientific documentation concerning SymPath(R), the company shall provide on its website within days and weeks to come, several reports, findings and other such documents.

For more information, do not hesitate to contact us by writing to info@neuro-agora.com and your request will be transferred to the appropriate persons and we will get back to you as soon as possible.

Contact: Neuro-Biotech Corp. Dr Claude Poulin 41 61 500 05 16 info@neuro-agora.com www.neuro-biotechcorp.com

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... N.J. , Sept. 19, 2014 Merck (NYSE: ... States and Canada , is teaming ... Desafiando La Diabetes: Logra Tus Metas , an educational program encouraging ... blood sugar -- a key treatment goal to help reduce the ... States are at a higher risk for developing type ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. Merlo ... CVS ), will speak before the National Press Club in ... the company,s recent move to stop selling tobacco products and ... future of health. "Dramatic changes in our health ... providers and government," Merlo has said. "CVS Health has a ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... , AT A GLANCE , Positron emission mammography ... ability to differentiate between benign and cancerous lesions. ... of suspicious lesions found. , An NIH-sponsored, ... cancer found that Positron Emission Mammography (PEM) scanners significantly ...
... , WOODCLIFF LAKE, N.J., Oct. 29 Eisai Inc. and ... the recipient of the 2009 C.A.R.E. Pharmacy Award. ... Greene is being recognized for the critical role she has ... Alzheimer,s disease. As a Geriatric Consultant Pharmacist with the ...
Cached Medicine Technology:High-Resolution Breast PET Improves Breast Cancer Detection 2High-Resolution Breast PET Improves Breast Cancer Detection 3Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 2Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease 3
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... of human cancers have abnormally upregulated chemical signals ... are controlled during tumor formation is not fully ... Fayngerts, PhD, both researchers in the department of ... of Medicine, University of Pennsylvania, and colleagues report ... cancer by targeting these pathways. , Lipid second ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker ... National Fire Protection Association (NFPA), a recognized international ... in a Memorandum of Understanding signed by both ... other stakeholders with information, guidance and access to ... and safety of workers in ready-made garment (RMG) ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... whether antiretroviral medications normally used to treat HIV infection ... as a vaginal gel or taken as oral tablets ... to Control the Epidemic (VOICE) or MTN-003, will involve ... infection in four African countries. The trial will test ...
... that some of the same antiretroviral (ARV) drugs used to ... Microbicide Trials Network have enrolled the first participants into a ... in women. The VOICE Study Vagina and Oral ... applying a vaginal microbicide gel containing an ARV every day ...
... , , ADDISON, ... announced today the presentation of results from the first ... in Washington D.C. September 16-18. The recently completed clinical study compared ... either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. ...
... Essman, acting on behalf of Hard to Treat Diseases, ... the actions of certain retail brokers who restricted trading ... these matters is sponsored by Investor Relations firm Mina ... Mina Mar is currently suing a stock chat board ...
... extend life and reduce risk of physical disability, researchers find ... who get regular exercise may live longer and be at ... , The research included almost 1,900 people born in 1920 ... 85. Those who did less than four hours of physical ...
... odds of disease, study shows, , WEDNESDAY, Sept. 16 ... replacement therapy women take to relieve menopausal symptoms seem ... face, a new French study suggests. , Overall, ... the risk of breast cancer, even when only used ...
Cached Medicine News:Health News:Clinical trial of antiretroviral-based HIV prevention strategies for women now under way 2Health News:Clinical trial of antiretroviral-based HIV prevention strategies for women now under way 3Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 2Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 3Health News:VOICE study, a major HIV prevention trial for women, is launched in Zimbabwe 4Health News:ULURU Inc. Presents Results of First Randomized Clinical Trial for Altrazeal(TM) at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Washington D.C. 2Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 2Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 3Health News:Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements 4Health News:Exercise Benefits Even the Oldest Old 2Health News:Timing, Type of HRT May Determine Breast Cancer Risk 2Health News:Timing, Type of HRT May Determine Breast Cancer Risk 3
Singe-pull lace design provides easy-on application to provide support and immobilization of the wrist while preserving finger mobility...
ManuTrain is an active wrist support that has optional features for increased stabilization....
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint uses ... the hand with ulnar deviation at the ... grasp or pinch. Radial and ulnar polycentric ... unimpeded flexion and extension. Padded, malleable finger ...
Medicine Products: